Plummeting 6.8%, way outperforming the market, Immune Design Corp. (NASDAQ:$IMDZ)’s shares are suffering a serious outlook.
Let’s take a look back on Immune Design’s last earnings report.
Narrower-than-expected Loss in Q2
The company incurred 2Q17 Loss of 54 cents per share, narrower than the Zacks Consensus Estimate of 65 cents.
2Q17
- The company’s total revenue was $0.7 million, down from $1.1 million in the year ago quarter
- Research and development expenses were down 4.6% to $10.9 million
- General and administrative expenses decreased by 1.5% to $3.9 million
Pipeline
Immune Design is developing multiple new products using its two discovery platforms, ZVex and GLAAS, in the field of immuno-oncology.
Of the two products, CMB305 is currently in trials, although data has not been optimal. The other, G100, is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study. In this trial, over a third of patients have achieved a partial response, and 50% of evaluable patients experience shrinkage of untreated distal lesions.
New Estimates
In the past month, investors have seen a downward trend in fresh estimates. At this time, Immune sees a new Growth Score of B. The stock sees a grade of F on the value side, situating it in the fifth quintile for investment strategy. Hence, the company’s stock is suitable for growth and momentum investors.
Featured Image: twitter
